Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
L T Foods Ltd, Jubilant Pharmova Ltd, Vishal Mega Mart Ltd, Hexaware Technologies Ltd are among the other stocks to see a surge in volumes on BSE today, 24 August 2026.
Lenskart Solutions Ltd recorded volume of 451.5 lakh shares by 10:45 IST on BSE, a 22.82 times surge over two-week average daily volume of 19.79 lakh shares. The stock lost 0.59% to Rs.657.65. Volumes stood at 4.03 lakh shares in the last session.
L T Foods Ltd saw volume of 2.65 lakh shares by 10:45 IST on BSE, a 7.36 fold spurt over two-week average daily volume of 36025 shares. The stock increased 10.10% to Rs.470.40. Volumes stood at 27636 shares in the last session.
Jubilant Pharmova Ltd witnessed volume of 1.45 lakh shares by 10:45 IST on BSE, a 7.23 times surge over two-week average daily volume of 20007 shares. The stock increased 2.17% to Rs.898.25. Volumes stood at 11654 shares in the last session.
Vishal Mega Mart Ltd clocked volume of 119.18 lakh shares by 10:45 IST on BSE, a 5.7 times surge over two-week average daily volume of 20.93 lakh shares. The stock gained 9.60% to Rs.113.55. Volumes stood at 61.05 lakh shares in the last session.
Hexaware Technologies Ltd recorded volume of 83433 shares by 10:45 IST on BSE, a 5.32 times surge over two-week average daily volume of 15669 shares. The stock gained 4.27% to Rs.555.85. Volumes stood at 15568 shares in the last session.
The said drug is primarily used to treat gastroesophageal reflux disease (GERD), heal acid-related damage to the esophagus.
The aforesaid tentative approval is subject to the expiry of the patent covering the currently listed Reference Listed Drug (RLD), which is expected to occur in December 2026. Final approval is anticipated upon such patent expiry.
The said approval follows successful completion of the pre-approval inspection (PAI) conducted by the United States Food and Drug Administration (USFDA) at the solid dosage manufacturing facility located at Roorkee.
Jubilant Pharmova is an integrated global pharmaceutical company with three business segments, namely pharmaceuticals, contract research and development services, and proprietary novel drugs. The company’s consolidated net profit declined 22.27% to Rs 119.40 crore, while net sales rose 18.60% to Rs 2,272.20 crore in Q4 FY26 compared with Q4 FY25.
The scrip shed 0.84% to settle at Rs 964.05 on Thursday, 25th June 2026. The stock market is shut today on account of Muharram.
Jubilant Pharmova announced that United States Food and Drug Administration (USFDA) has concluded an inspection of Jubilant HollisterStier LLC (JHS)'s contract manufacturing facility located in Spokane, WA. U.S.A on 17 June 2026.
The USFDA had issued eight (8) observations, none of which are related to sterility assurance concerns.
Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma, Singapore, a wholly owned subsidiary of the company.
Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma Limited, Singapore, a wholly owned subsidiary of Jubilant Pharmova.
Shares of Jubilant Pharmova shed 0.94% to Rs 965.45 on the BSE.